LARCT-US Swedish prospective cohort study published! 273 pts with high risk rectal cancer (RAPIDO inclusion, but older and more advanced tumors) treated with SCRT and 2 less chemo cycles than RAPIDO. 3-yr LRR 6% (no more events past 3-years). Real🌍 data. thelancet.com/journals/eclin…

We have a new residency overview video! Watch us cram everything amazing about Duke Cancer #RadOnc into a six-minute highlight reel ✨ youtu.be/gjcxx0g8Ac8 #Match2025 #WomenWhoCurie #WeWhoCurie ARRO ACROresident

Chief resident Dr. Acklin-Wehnert on what residency at Duke Cancer offers ✨ See more about our program at radonc.duke.edu/education/radi… #Match2025 #MedEd #WomenWhoCurie #WeWhoCurie #MedTwitter #RadOncTwitter #RadOnc

Most radiation oncologists and hospital systems are unaware of the significant market potential for using radiotherapy to treat benign musculoskeletal conditions. In the United States alone, there are over 40 million patients suffering from these conditions, many of which could

Dr. Abhishek ("Shake") Kumar, MD MAS, one of our #RadOnc chiefs, on our residency's innovative and empowering (and VERY beloved by residents) Durham VA Health Care System rotation #Match2025 #MedEd #MedTwitter #RadOncTwitter

Calling all rad onc med students!! We have a great day planned for you 👏 Michael LeCompte Emily MacDuffie Abhishek ("Shake") Kumar, MD MAS

NEW: RT for nonmalignant diseases webinar series. This series will provide an overview of historical & contemporary indications for radiation therapy in the treatment of nononcological conditions. six-part series begins 8/28 (live+onDemand). Register now: ow.ly/ksB050T2jbI

Coach Jon Scheyer chopping it up with Duke general surgery residents this AM!

🚨New Book on Low-Dose Radiation for Painful Musculoskeletal Conditions🚨 Free Download Now Available Over the past year, there has been a remarkable surge of interest in using low-dose radiotherapy to treat painful musculoskeletal conditions like osteoarthritis, plantar

Penn Radiation Oncology Residency If I were doing rad onc residency now, I would make sure to spend a few months with Vedang Murthy and Priyamvada Maitre at Tata Memorial Hospital. Tata Memorial Hospital 1.Unmatched clinical volume and diversity (I watched Vedang consult/evaluate ~100 patients per day. I saw

Calling all #MedStudents interested in #RadOnc: Meet us at #ASTRO24! Chat with our Duke Cancer residents and PD at a meet and greet at Lostandfounddc at 4 p.m. on 9/29. RSVP at duke.is/DukeASTROMeet ✨ can't wait to meet y'all! ARRO ASTRO #Match2025 #WomenWhoCurie

Dr. Qazi on Duke #RadOnc's resident culture. Our program PDs have a specific focus on prioritizing resident wellness 💙 #Match2025 #MedTwitter #RadOncRes

Sharing our newest paper by the talented Mihir Shanker presenting the treatment of the the often deadly RCC IVC thrombus. Utilizing a 1.5 MRI linac we were able to effectively align high dose radiation to what is otherwise a CT invisible lesion doi.org/10.1002/bco2.4…

📣Single fraction palliative RT for painful liver cancer vs best supportive care #rct ➡️4/10 pain @ base ➡️liver Mets/#HCC ➡️ 67% vs 22% SS pain improv Mark Suchanof with RT 💪 ➡️no sig inc side effects ➡️3m survival 51% vs 33% ns Laura Dawson Radiation Medicine Program Cancer Research @UCC thelancet.com/journals/lanon…

Retrospective series of short v long course RT in rectal cancer Despite achieving similar rates of complete response (~44%), organ preservation w LC better (2yr 40% v 31%) German AIO18.1 RCT to provide definitive data, but for now LC TNT remains preferred reg for non-op intent

#PACE A published in European Urology! SBRT vs Radical prostatectomy. Spread the word #SBRT should be discussed with eligible patients ⁦Dr Shaun Tolan⁩ Alison Tree 💙⁩ ⁦Clive Peedell⁩ Dr. Andrew Loblaw⁩ ⁦Prof Emma Hall⁩ Prof Joe O'Sullivan⁩ authors.elsevier.com/sd/article/S03…

Adriatic is the new Pacific as durva improves PFS and OS in LS-SCLC! So proud of my mentor Prof. Suresh Senan who lead this effort - lots to unpack here on PCI, RT schedule, and choice of platinum chemo #LCSM #RadOnc Dr. David Palma Ben Slotman Shankar Siva Drew Moghanaki 🐕

Excellent discussion by Shilpa Gupta at #ESMO24 on chemoRT for MIBC and CM-901. Upcoming trials (SWOG/NRG1806, KEYNOTE-992, SunRISe-2) are set to further explore IO-trimodality therapy in MIBC. #cancer #oncology @oncoalert ESMO - Eur. Oncology Toni Choueiri, MD Emre Yekedüz Neeraj Agarwal, MD, FASCO 𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏

Yesterday Emily Grist showed out groundbreaking #Decipher outcome with Decipher score predictive of docetaxel benefit. A first Veracyte, Inc. Elai Davicioni The ICR MRC Clinical Trials Unit at UCL #Stampede AttardLab

Randomized phase 2 trial evaluating SBRT to the Primary Breast Cancer +/- Durvalumab +/- Oleclumab combined with Neoadjuvant Chemotherapy for Early-Stage High Risk ER+/HER2- 👉 high rates of pCR especially in PD-L1 neg pts